Myofibroblast Senescence in Pulmonary Fibrosis
Myofibroblast Senescence in Pulmonary Fibrosis
批准号:
8916533
负责人:
Victor J. Thannickal
金额:
$32.08万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-01 至 2019-05-31
关键词:
AccountingAffectAgeAgingAnimal ModelAntioxidantsApoptosisApplications GrantsAttenuatedBioenergeticsBiologicalBlood VesselsCell AgingCicatrixClinicalDataDevelopmentDiagnosisDiseaseEnzymesEquilibriumExhibitsFDA approvedFibroblastsFibrosisGasesGene ExpressionGenesGeneticHamman-Rich syndromeHealthHeartHomeostasisHumanHuman CharacteristicsIncidenceKidneyLaboratoriesLeadLinkLiverLungLung diseasesMediatingMitochondriaModelingMolecularMorbidity - disease rateMusMyofibroblastNADPH OxidaseNuclearOxidation-ReductionOxidative StressOxidative Stress InductionPathogenesisPathway interactionsPharmaceutical PreparationsPhenotypePrevalencePulmonary FibrosisReactive Oxygen SpeciesRegulationResearchResistanceResolutionRespiratory FailureRoleSmall Interfering RNAStructure of parenchyma of lungSurvival RateTestingTimeTissuesage relatedagedbody systemburden of illnesseffective therapyfibrogenesishuman subjectimpaired capacityin vivoinhibitor/antagonistinsightlung injurymitochondrial dysfunctionmortalitynovelnovel therapeutic interventionnuclear factor-erythroid 2older patientresponsesenescencetranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Human fibrotic disorders affect many organ systems including heart, blood vessels, kidney, liver and lung. The most common fibrotic lung disease, idiopathic pulmonary fibrosis (IPF) is a disease of aging carries a high morbidity and mortality, with a median survival rate of less than three years. There are currently no U.S. FDA-approved anti-fibrotic drugs. The incidence and prevalence of IPF increase drastically with age; however, despite this strong association, cellular/molecular mechanisms that account for the aging predilection to fibrotic disease have not been elucidated. Recent studies from our laboratory indicate that the biological effects of the ROS-generating enzyme, NADPH oxidase-4 (Nox4) is determined by the capacity of myofibroblasts (MFbs) to maintain redox homeostasis via the induction of the antioxidant response transcription factor, nuclear factor-like 2 (Nrf2), a respons that is deficient with aging. Loss of this cellular homeostatic mechanism results in the emergence of a senescent and apoptosis-resistant phenotype of MFbs, at least in part related to mitochondrial dysfunction. Human subjects with IPF exhibit elevated expression of Nox4 and decreased Nrf2 expression in myofibroblastic foci, supporting this cellular redox imbalance in a human fibrotic disease. In contrast to self-limited, resolving fibrosis in young mice, aged mice manifest an impaired capacity for resolution of fibrosis. This represents, to our knowledge, the first aging model of fibrosis that recapitulates the non-resolving nature of human IPF. The central hypothesis to be tested in this project is that an imbalance of Nox4-Nrf2 induces sustained oxidative stress that induces MFb senescence and apoptosis resistance, leading to persistent fibrosis associated with aging. Our specific aims are to: (1) Determine mechanisms for the (dys)regulation of Nrf2 expression/induction by oxidative stress with cellular senescence; (2) Determine the role of Nox4-Nrf2 imbalance and mitochondrial bioenergetics in promoting Fb senescence; and (3) Determine whether conditional genetic deletion of Nrf2 in Fbs mediates persistent fibrosis in young mice; and whether Nrf2 induction or Nox4 inhibition (by pharmacologic approaches) promotes fibrosis resolution in aged mice. This grant application is responsive to PA-10-014: Development and Characterization of Animal Models for Aging Research. The completion of the aims in this project will: (a) establish a disease-relevant animal model of non-resolving fibrosis; (b) define mechanisms for the loss of redox homeostatic control in MFbs; (c) establish mechanistic links between mitochondrial dysfunction and senescence; and (d) provide proof-of-concept that correction of cellular redox balance will promote fibrosis resolution and lead to the development of novel therapeutic approaches to non-resolving fibrotic disorders such as IPF.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AMPK in the Development and Resolution of Lung Fibrosis
-
批准号:10320917
-
项目类别:
-
资助金额:$52.85万
-
财政年份:2019
-
负责人:Victor J. Thannickal
-
依托单位:
AMPK in the Development and Resolution of Lung Fibrosis
-
批准号:10083647
-
项目类别:
-
资助金额:$52.85万
-
财政年份:2019
-
负责人:Victor J. Thannickal
-
依托单位:
Sirtuins in Lung Aging and Fibrosis
-
批准号:10513291
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Victor J. Thannickal
-
依托单位:
Sirtuins in Lung Aging and Fibrosis
-
批准号:9210543
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Victor J. Thannickal
-
依托单位:
Sirtuins in Lung Aging and Fibrosis
-
批准号:10610127
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Victor J. Thannickal
-
依托单位:
Myofibroblast Senescence in Pulmonary Fibrosis
-
批准号:8786336
-
项目类别:
-
资助金额:$33.08万
-
财政年份:2014
-
负责人:Victor J. Thannickal
-
依托单位:
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease
-
批准号:10218247
-
项目类别:
-
资助金额:$149.99万
-
财政年份:2013
-
负责人:Victor J. Thannickal
-
依托单位:
Administrative and Biostatistical Core
-
批准号:10218248
-
项目类别:
-
资助金额:$10.48万
-
财政年份:2013
-
负责人:Victor J. Thannickal
-
依托单位:
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease
-
批准号:9980973
-
项目类别:
-
资助金额:$53.23万
-
财政年份:2013
-
负责人:Victor J. Thannickal
-
依托单位:
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease
-
批准号:8735177
-
项目类别:
-
资助金额:$191.72万
-
财政年份:2013
-
负责人:Victor J. Thannickal
-
依托单位:
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease
-
批准号:10358400
-
项目类别:
-
资助金额:$135.86万
-
财政年份:2013
-
负责人:Victor J. Thannickal
-
依托单位:
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease
-
批准号:10473592
-
项目类别:
-
资助金额:$119.42万
-
财政年份:2013
-
负责人:Victor J. Thannickal
-
依托单位:
Redox Regulation of Metabolic Reprogramming in Activated Myofibroblasts
-
批准号:10218252
-
项目类别:
-
资助金额:$39.08万
-
财政年份:2013
-
负责人:Victor J. Thannickal
-
依托单位:
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease
-
批准号:8554470
-
项目类别:
-
资助金额:$186.96万
-
财政年份:2013
-
负责人:Victor J. Thannickal
-
依托单位:
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease
-
批准号:9752650
-
项目类别:
-
资助金额:$193.94万
-
财政年份:2013
-
负责人:Victor J. Thannickal
-
依托单位:
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease
-
批准号:8890182
-
项目类别:
-
资助金额:$192.7万
-
财政年份:2013
-
负责人:Victor J. Thannickal
-
依托单位:
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease
-
批准号:9115701
-
项目类别:
-
资助金额:$195.64万
-
财政年份:2013
-
负责人:Victor J. Thannickal
-
依托单位:
Rho-Kinase Pathway in Pulmonary Fibrosis
-
批准号:8262378
-
项目类别:
-
资助金额:$43.95万
-
财政年份:2011
-
负责人:Victor J. Thannickal
-
依托单位:
Rho-Kinase Pathway in Pulmonary Fibrosis
-
批准号:8073323
-
项目类别:
-
资助金额:$43.95万
-
财政年份:2011
-
负责人:Victor J. Thannickal
-
依托单位:
Training Program in Lung Biology and Translational Medicine
-
批准号:8313943
-
项目类别:
-
资助金额:$33.85万
-
财政年份:2010
-
负责人:Victor J. Thannickal
-
依托单位:
海外基金